BiotechTube

Lenvatinib + Pembrolizumab

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumors

Conditions

Tumors

Trial Timeline

Jul 22, 2015 → Jul 11, 2022

NCT ID
NCT02501096

About Lenvatinib + Pembrolizumab

Lenvatinib + Pembrolizumab is a phase 1/2 stage product being developed by Eisai for Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02501096. Target conditions include Tumors.

What happened to similar drugs?

8 of 20 similar drugs in Tumors were approved

Approved (8) Terminated (4) Active (8)
✅Everolimus (RAD001)NovartisApproved
✅everolimusNovartisApproved
✅Imatinib MesylateNovartisApproved
✅NilotinibNovartisApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
✅Sunitinib Malate (SU011248)PfizerApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT04645602Phase 1Recruiting
NCT04209660Phase 2Active
NCT03776136Phase 2Completed
NCT03609359Phase 2Completed
NCT03006887Phase 1Completed
NCT02501096Phase 1/2Completed

Competing Products

20 competing products in Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
E7050EisaiPhase 1
29
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
CixutumumabEli LillyPhase 1
29
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27
ZN-c3 + Bevacizumab + PembrolizumabZentalis PharmaceuticalsPhase 1
11
IMC-18F1Eli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
ACR-2316Acrivon TherapeuticsPhase 1
26
LY2875358 + Erlotinib + GefitinibEli LillyPhase 1
29
Tomivosertib (eFT-508)eFFECTOR TherapeuticsPhase 2
25
SPYK04Chugai PharmaceuticalPhase 1
33
AUBE00 + CetuximabChugai PharmaceuticalPhase 1
36
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
ERY974Chugai PharmaceuticalPhase 1
29
DS3610aDaiichi SankyoPhase 1
36
Tivantinib (ARQ 197) Capsule + Tivantinib (ARQ 197) Tablet + Tivantinib (ARQ 197) Capsule D, oralDaiichi SankyoPhase 1
29